ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Division Spotlight
Education, Training & Workforce Development
The Education, Training & Workforce Development Division provides communication among the academic, industrial, and governmental communities through the exchange of views and information on matters related to education, training and workforce development in nuclear and radiological science, engineering, and technology. Industry leaders, education and training professionals, and interested students work together through Society-sponsored meetings and publications, to enrich their professional development, to educate the general public, and to advance nuclear and radiological science and engineering.
Meeting Spotlight
2024 ANS Annual Conference
June 16–19, 2024
Las Vegas, NV|Mandalay Bay Resort and Casino
Standards Program
The Standards Committee is responsible for the development and maintenance of voluntary consensus standards that address the design, analysis, and operation of components, systems, and facilities related to the application of nuclear science and technology. Find out What’s New, check out the Standards Store, or Get Involved today!
Latest Magazine Issues
Jun 2024
Jan 2024
Latest Journal Issues
Nuclear Science and Engineering
August 2024
Nuclear Technology
July 2024
Fusion Science and Technology
Latest News
Orano Med inaugurates Pb-212 production facility in Indiana
Guillaume Dureau of Orano Group (left) and Orano Med’s Julien Dodet cut the ribbon on the new ATLabs Indianapolis. (Photo: Orano)
Orano Group subsidiary Orano Med, a developer of targeted alpha therapies for oncology, inaugurated its first ATLab (Alpha Therapy Laboratory) earlier this month. Located in Brownsburg, near Indianapolis, Ind., ATLab Indianapolis is an industrial-scale pharmaceutical facility dedicated to the production of lead-212–based radioligand therapies.
Targeted alpha therapy has shown to be effective in treating various oncological diseases, combining the natural ability of biological molecules to target cancer cells with the short-range cell-killing capabilities of alpha emissions generated by Pb-212. With a half-life of 10.64 hours, along with a decay product of the short-lived alpha-emitter bismuth-212, Pb-212 allows for the possible synthesis and purification of complex radiopharmaceuticals with minimum loss of radioactivity during preparation.
The development of radiopharmaceuticals has long been hampered by the difficulty of manufacturing and distribution on an industrial scale, Orano said, adding that the construction of ATLab Indianapolis is a major step toward making these new treatments available to cancer patients with high unmet needs in North America.
October 24–27, 2016
Sendai, Japan
General Chair:
Reiko Fujita (Chief Fellow, Toshiba Corporation)
Co-Chairs:
Tadafumi Koyama (Central Research Inst of Elec Pwr Industry)
Yasuji Morita (Japan Atomic Energy Agency)